A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

Woman and Man

| Country :
| organs :
| Specialty :

Extract

The primary objective is to compare survival rate at 12 months in Vx-001 treated vs placebo treated patients. El principal objetivo es comparar la tasa de supervivencia global (SG) tras 12 meses con tratamiento con Vx-001 con la de los pacientes tratados con placebo.

Inclusion criteria

non-small cell lung cancer,Cáncer de Pulmón no microcítico

Kusajili – Clinical trials directory

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0...

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

Woman and Man

Extract

Inclusion criteria

Links